TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05030129
Drug: Ergoloid Mesylates
Normalized name: Ergoloid Mesylates
DrugBank: Ergoloid mesylate (DB01049)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ergoloid mesylates 1 mg will be mixed with methyl cellulose and placed in a size 00 capsule. During the EM Treatment Period (Period 1) and 5-HTP/EM Treatment Period (Period 2), subjects will take 1 capsule of EM 3 times per day.
Study: NCT05030129
Drug: Matching placebo for Ergoloid mesylates
Normalized name: Ergoloid Mesylates
DrugBank: Ergoloid mesylate (DB01049)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Matching placebo for Ergoloid mesylates will be ascorbic acid powder in identical size 00 capsules. During the 5-HTP Treatment Period (Period 3) and Placebo Treatment Period (Period 4), subjects will take 1 capsule of matching placebo for EM 3 times per day.
Study: NCT05030129
Drug: Matching placebo for 5-Hydroxytryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Matching placebo for 5-Hydroxytryptophan will be ascorbic acid powder in identical size 00 capsules. During the EM Treatment Period (Period 2) and Placebo Treatment Period (Period 4), subjects will take 1 capsule of matching placebo for 5-HTP 3 times per day.
Study: NCT05643495
Drug: VX-864
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets for oral administration.
Study: NCT06654804
Drug: Perflutren lipid
Normalized name: perflutren lipid microspheres
DrugBank: Perflutren (DB00556)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bolus injection of contrast during spinal decompression surgery for the treatment of traumatic spinal cord injury. Ultrasound imaging will then be used to collect images of the spinal cord injury to record perfusion, inflow and washout.
Study: NCT06587620
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Start IV infusion of a loading dose of tranexamic acid 10 mg/kg completed to 50 ml saline over 10 min before induction of anesthesia. IV infusion of tranexamic acid at a dose of 1 mg/kg/h immediately after induction till 15 min before the end of surgery.
Study: NCT06587620
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Start IV infusion of a loading dose of dexmedetomidine 1ug/kg completed to 50 ml saline over 10 min before induction of anesthesia. IV infusion of dexmedetomidine 0.3-0.7 µg/kg/h immediately after induction to maintain Mean Arterial Pressure (MAP) between 60-70 mmHg till 15 min before the end of surgery.
Study: NCT03651752
Drug: Diphenylcyclopropenone (DPCP) Ointment
Normalized name: Diphenylcyclopropenone
DrugBank: Diphencyprone (DB12173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will be administered a sensitization dose of 0.05 mL 0.4% DPCP ointment formulation topically in the inner aspect of the upper right arm at Day -16, and 0.05 mL of four concentrations (0.1, .05, 0.01, 0.005%), prepared through dilutions in the ointment vehicle, topically on the inner aspect of the left thigh at Day -2. The weakest strength that may cause a minimal reaction (DTH skin reaction score of 1+) after two days will be chosen, and 0.75-1 g of that concentration will be applied to the scalp starting at Week 1 and administered subsequently twice a week for 18 weeks
Study: NCT06169410
Drug: nab-paclitaxel, lobaplatin, and S-1 combined with ramucirumab
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients in Experimental group will be given ramucirumab (8mg/kg) by intravenous drip on the first day of each cycle, 3 weeks a cycle.
Study: NCT06035068
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green (ICG) is a fluorescent dye that has been used for the imaging of cancers in the body for more than 30 years.
Study: NCT05784844
Drug: Meropenem
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbapenem antibiotic
Study: NCT05784844
Drug: Micafungin
Normalized name: Micafungin
DrugBank: Micafungin (DB01141)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Echinocandin antifungal
Study: NCT04762589
Drug: RT001
Normalized name: Risankizumab
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: RT001 8.64 g/d (3 capsules TID) for 1 month followed by 5.76 g/d (3 capsules BID) for an additional 5 months
Study: NCT05833763
Drug: Glofitamab
Normalized name: Glofitamab
DrugBank: Glofitamab (DB16371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glofitamab is provided as liquid concentrate for IV infusion. Each vial contains 10mg of glofitamab.
Study: NCT05833763
Drug: Pirtobrutinib
Normalized name: Pirtobrutinib
DrugBank: Pirtobrutinib (DB17472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirtobrutinib is supplied as immediate release film-coated tablets containing 50 mg, or 100 mg of active compound. Tablets are supplied in labelled, HDPE bottles and sealed with child-resistant closures.
Study: NCT05833763
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab is provided as a single dose 1000 mg liquid concentrate for infusion containing of 25 mg/mL obinutuzumab.
Study: NCT05833763
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab is provided as a liquid concentrate for IV infusion. Each vial contains 200mg/10mL concentrate solution
Study: NCT04894266
Drug: Apabetalone
Normalized name: Apabetalone
DrugBank: Apabetalone (DB12000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apabetalone 100mg BID
Study: NCT04871451
Drug: ABP-450
Normalized name: ABPC
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ABP-450 (prabotulinumtoxinA) contains a 900kDA botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
Study: NCT05101122
Drug: Dosing 1: Atomoxetine
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration at bedtime
Study: NCT05101122
Drug: AD313
Normalized name: Aducanumab
DrugBank: Aducanumab (DB12274)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escalating dose of AD313; Oral administration at bedtime
Study: NCT05533606
Drug: Beta-Lactam Drugs
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: During hospitalization，patients used Beta-Lactam drugs.
Study: NCT05718921
Drug: YR001 Dose A on low body surface area
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part A: Single topical dose
Study: NCT05718921
Drug: YR001 Dose A on middle body surface area
Normalized name: risankizumab
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Part A: Single topical dose
Study: NCT05718921
Drug: YR001 Dose A on high body surface area
Normalized name: risankizumab
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Part A: Single topical dose
Study: NCT05718921
Drug: YR001 Dose A on high body surface area twice daily
Normalized name: risankizumab
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Part B: Multiple topical dose
Study: NCT05999292
Drug: 68Ga-R8760 injection at pre-defined dose levels
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET/CT imaging at predefined timepoints
Study: NCT05999292
Drug: 68Ga-R8760 injection
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET/CT imaging at a single timepoint
Study: NCT04965818
Drug: Futibatinib and Binimetinib
DrugBank: Binimetinib (DB11967)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive futibatinib once daily in combination with binimetinib twice daily by oral administration on a 21-day cycle
Study: NCT02039869
Drug: Sucralfate
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coating agent for damaged intestinal lining.
Study: NCT05346731
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondnsetron will be administered at a dose of 0.15 mg/kg IV/PO every 8 hours on the day(s) of chemotherapy and 3 days after completion of chemotherapy
Study: NCT05346731
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone will be administered at a dose of 5 mg/m2 intravenously/orally once on the day(s) of chemotherapy and 3 days after completion of chemotherapy;
Study: NCT05346731
Drug: Aprepitant
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant will be administered based on body weight:~body weight 30-40 kg: days 1-3 - 80 mg orally; body weight \> 40 kg: day 1 - 125 mg orally, days 2, 3 - 80 mg orally
Study: NCT05346731
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine will be administered at a dose of 0.07 mg/kg orally on the day(s) of chemotherapy and 3 days after completion of chemotherapy (rounded up to the maximum multiple of 2.5 mg, maximum daily dose of 5 mg).
Study: NCT05255900
Drug: Metyrapone Capsules
Normalized name: Metyrapone Capsules
DrugBank: Metyrapone (DB01011)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exposure to 24 weeks of treatment with metyrapone
Study: NCT05806580
Drug: Relma-cel
Normalized name: relma-cel
DrugBank: Relmacabtagene autoleucel (DB18979)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who have undergone at least one disease assessment after initial Relma-cel treatment and have not achieved complete remission may receive a second treatment based on clinical practice. The specific dosage will be determined by the investigator according to the patient's condition and available dose reserves.
Study: NCT05647408
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The nominal doses were similar, volunteers were randomly assigned to receive a single dose of DXM by IV bolus of 1.5 mL (equivalent to 6 mg of dexamethasone) or the same dose intranasally by using a Mucosal Atomization Device (MAD Nasal). allowing direct pharmacokinetic comparison without dose normalization. Venous blood samples were obtained via an indwelling catheter before administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12 and 24 h for DXM. Plasma was separated and frozen at -70 °C for further analysis.
Study: NCT04427241
Drug: Cerebrolysin
Normalized name: cerebrolysin
DrugBank: Cerebrolysin (DB16599)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml cerebrolysin + 70 ml normal saline, days 4-17, once/day, intravenously
Study: NCT04427241
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 ml normal saline, days 4-17, once/day, IV
Study: NCT05277987
Drug: HEC-016(0.5×10^6 CAR-T Cells)
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial dose is set to 0.5 × 10\^6 car-t cells / kg, and 3 \~ 6 subjects are expected to be included in the dose group. DLT was observed within 28 days after cell infusion.
Study: NCT05277987
Drug: HEC-016(0.5×10^6.5 CAR-T Cells)
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Second dose is set 0.5 × 10\^6.5 car-t cells / kg, and 3 \~ 6 subjects are expected to be included in the dose group.
Study: NCT05277987
Drug: HEC-016(0.5×10^7 CAR-T Cells)
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Third dose is set 0.5 × 10\^7 car-t cells / kg, and 3 \~ 6 subjects are expected to be included in the dose group.
Study: NCT05623878
Drug: 68Ga-labeled NY108
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a tracer (20-40mcg, IV) dose of 68Ga (2-5mCi) labelled NY108.
Study: NCT06046937
Drug: Monolaurin
Normalized name: MONOLAURIN
DrugBank: Glyceryl laurate (DB16635)
Approvals — FDA: no, EMA: no, PMDA: no
Description: applied thinly twice a day
Study: NCT06046937
Drug: Mupirocin ointment
Normalized name: Mupirocin Ointment
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: applied thinly twice a day
Study: NCT06091891
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Without ROTEM-guidance, we maintain tranexamic acid infusion at 10mg/kg/h until the end of the surgery.
Study: NCT06091891
Drug: Tranexamic acid infusion under ROTEM-guidance
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If diffuse bleeding occurs during surgery, we perform ROTEM testing and administer tranexamic acid based on the test results.
Study: NCT04204967
Drug: Fentanyl Transdermal System
Normalized name: Fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: in the experimental arm transdermal fentanyl will be administered with a starting dose of 50 mcg/hr simultaneously with the preexistent remifentanil continue infusion. Remifentanil infusion rate will be increased or decreased based on PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected at each visit. After randomization, the transdermal fentanyl dose can be modified every 24 hours according to the study protocol to achieve the desired effect in terms of PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected
Study: NCT05744466
Drug: Deucravacitinib
Normalized name: Deucravacitinib
DrugBank: Deucravacitinib (DB16650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed by treating clinician
Study: NCT05744466
Drug: Apremilast
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: As prescribed by treating clinician
Study: NCT04383210
Drug: Seribantumab
Normalized name: Seribantumab
DrugBank: Seribantumab (DB11857)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-HER3 monoclonal antibody
Study: NCT04862585
Drug: Cimetidine
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV and/or PO
Study: NCT04862585
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV and/or PO
Study: NCT04862585
Drug: Diphenhydramine
Normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV and/or PO
Study: NCT04862585
Drug: Famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV and/or PO
Study: NCT04862585
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly or every 14 day dosing
Study: NCT04862585
Drug: Ranitidine
Normalized name: Ranitidine
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV and/or PO
Study: NCT06166615
Drug: Ramosetron
Normalized name: ramosetron
DrugBank: Ramosetron (DB09290)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Ramosetron (a 5-HT3 receptor antagonist) has been developed as an effective treatment for irritable bowel syndrome-diarrhea (IBD-D) and is used to decrease intestinal motility, stiffen stool consistency, and reduce the number of urgency bowel movements. Since one of the goals of treatment for fecal incontinence is the maintenance of stool consistency, this agent is expected to be effective in treating fecal incontinence.
Study: NCT06166615
Drug: Psyllium
Normalized name: Psyllium
DrugBank: Plantago seed (DB11097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium was found to be the most effective at improving symptoms of fecal incontinence among several dietary fibers in a randomized, controlled, single-blind study and is currently used as a first-line treatment for fecal incontinence.
Study: NCT05939193
Drug: Forced administration of furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Forced administration of furosemide
Study: NCT05939193
Drug: Routine administration of furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine administration of furosemide
Study: NCT05638594
Drug: Pyrotinib
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320mg, qd
Study: NCT05638594
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8 mg/kg first dose, then 6 mg/kg，q3w
Study: NCT05638594
Drug: Dalpiciclib
Normalized name: Dalpiciclib
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125mg , qd，d1-21, q4w
Study: NCT05638594
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5mg，qd
Study: NCT05638594
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 840 mg first dose, then 420 mg, q3w
Study: NCT05638594
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2, q3w
Study: NCT05638594
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 6, q3w
Study: NCT05674656
Drug: Dolutegravir/Rilpivirine FDC
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dolutegravir/Rilpivirine will be administered.
Study: NCT05378191
Drug: COMIRNATY
Normalized name: Comirnaty
DrugBank: Tozinameran (DB15696)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose of COMIRNATY
Study: NCT05850455
Drug: Dexmedetomidine Hydrochloride 'Precedex' combined with
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine Hydrochloride which is an Alfa 2 receptor agonist
Study: NCT05850455
Drug: Local infiltration with Lidocaine HCL 1%'Debocaine'
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine 1% which is a local analgesic as local infiltration
Study: NCT06284265
Drug: Raphamin
Normalized name: Allantoin 0.007 g in 0.7 g TOPICAL POWDER [RAPHAGEN POWDE R]
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet for oral use.
Study: NCT04969939
Drug: Semaglutide 2.4 mg and NNC0165-1875 2.0 mg
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: NNC0165-1875 will be co-escalated once-weekly subcutaneously with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.
Study: NCT04969939
Drug: Semaglutide 2.4 mg and placebo 2.0 mg
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: NNC0165-1875 placebo will be co-escalated subcutaneously once-weekly with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.
Study: NCT04969939
Drug: Semaglutide 2.4 mg and NNC0165-1875 1.0 mg
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: NNC0165-1875 will be co-escalated subcutaneously once-weekly with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.
Study: NCT04969939
Drug: Semaglutide 2.4 mg and placebo 1.0 mg
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: NNC0165-1875 placebo will be co-escalated subcutaneously once-weekly with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.
Study: NCT05169229
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As a placebo added to the allograft.
Study: NCT04843098
Drug: TL117
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TL117 capsules orally once daily
Study: NCT04843098
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel (80 mg/m2) administered intravenously (IV) on Days 1, 8, and 15 of a 28-day treatment cycle.
Study: NCT05689372
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive Ozempic (solution for injection 1.34 mg/ml (Semaglutide s.c.) according to routine clinical practice conditions for 26 weeks. The physician will determine the dose of Ozempic in accordance with the K-PI.
Study: NCT04126135
Drug: Cytisine
Normalized name: Cytisine
DrugBank: Cytisine (DB09028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take a 25-day course of Cytisine tablets started during the 4 days before the quit date. They will be asked to reduce smoking during this time.
Study: NCT04126135
Drug: Nicotine Replacement Therapy (NRT)
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects are asked to completely stop smoking on their quit day and use a daily NRT patch for 25 days.
Study: NCT06012916
Drug: Esketamine nasal spray
Normalized name: esketamine Nasal Spray
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is an observational study. The Esketamine nasal spray is administered by the attending physician during a regular treatment appointment at the Interventional Psychiatry Clinic. Esketamine dosages may range between 28-84mg. The study does not interfere with the individual treatment plan in any way.
Study: NCT05823571
Drug: Itacitinib
Normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A standard 3+3 design will be used to evaluate the safety of itacitinib plus different immunosuppression regimens. This study has four predefined Regimens that will be explored in the optimal Regimen-finding phase and are listed in Table 2 of the protocol. Itacitinib will be given in conjunction with each of four different regimens for immunosuppression. Regimen 1 is the current standard for our BMT patients, with a duration of MMF from day 5-35. Regimen 2 will decrease the duration of MMF from 35 to day 25. Regimen 3 will decrease the duration of MMF from 35 to day 15. Regimen 4 will eliminate MMF altogether. We will start with Regimen 1, which combines itacitinib with the current standard of immunosuppression. Progression through cohorts (Regimens) will be based on a standard 3+3 design to find the optimal regimen.